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Abstract
Rationale: Small bowel adenocarcinoma (SBA) is an uncommon gastrointestinal cancer, thus limited data about treatment for
advanced disease are available. The lack of specific guidelines has justified the use of therapeutic protocols usually applied in
advanced colorectal cancer. Few and preliminary data have suggested possible clinical benefit from the use of target therapy such as
bevacizumab and cetuximab.
Patientconcerns:We present the case of a young woman who was admitted to the emergency department for acute abdominal
pain, nausea, and vomiting related to a jejunal stenosis.
Diagnoses: An enteroscopy with jejunal biopsy showed poorly differentiated cancerous cells suggestive for primary intestinal
cancer. There were no signs of metastatic disease at radiological evaluation. A jejunal resection was subsequently carried out and the
diagnosis of mucinous adenocarcinoma of the jejunum was confirmed.
Interventions: The computed tomography scan performed 1 month after surgery showed metastatic disease. Therefore, the
patient received combined protocols of chemotherapy and either bevacizumab or the anti-epidermal growth factor receptor (EGFR)
panitumumab.
Outcomes: A partial response (PR) was achieved with Folfox plus panitumumab and a maintenance therapy with panitumumab is
being conducted with a mild toxicity and a progression free survival of 19 months since the beginning of panitumumab.
Lessons: This is, to the best of our knowledge, the first report in the literature of a patient with SBA who has benefitted from
panitumumab with an overall survival of 83 months.
Abbreviations: CRC = colorectal cancer, EGFR = epidermal growth factor receptor, PR = partial response, SBA = small bowel
adenocarcinoma, VEGF = vascular endothelial growth factor.
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Small bowel adenocarcinoma (SBA), which accounts for about
one-third of all cancers of the small bowel, is considered a rare
tumor. The majority of SBA develops sporadically though some
genetic conditions such as Lynch syndrome, familial adenomatous
polyposis, and Peutz-Jeghers syndrome cause an increased risk of
the disease. There is a slightmale predominance and the duodenum
is themost common tumor site. Unlike BRAFmutations,which areEditor: N/A.
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1uncommon in sporadic SBA, the rate ofK-rasmutations, as high as
40% to 60%, resembles that of colorectal cancer (CRC).[1]
Conversely, the presence of microsatellite instability, which is
reported up to 35%, is more frequent than that reported in CRC.
Clinical studies regarding systemic treatment of advanced SBA are
limited.[2–5] The lack of high-level data has prevented fromwriting
practical guidelines. Based on either retrospective or phase-2
studies, the combination of fluoropyrimidines and oxaliplatin is
regarded as the standard regimen for advanced and metastatic
disease.[2,3] Because in tissuemicroarrays of SBA a high percentage
of expression of both epidermal growth factor receptor (EGFR)
and vascular endothelial growth factor (VEGF)was demonstrated,
a possible benefit from therapeutic strategies targeting EGFR and
VEGF receptor is expected to be.[6] Nonetheless, the use of target
therapy has been rarely investigated, testified by only a few case
reports and 3 clinical studies (Table 1). Within the context of anti-
EGFR therapy, to the best of our knowledge, only 2 experiences
referred to chemotherapy associated with cetuximab.[10,11] Here,
the case of a patient, who received a combination of chemotherapy
and the monoclonal antibody panitumumab for a jejunal
adenocarcinoma, is described.2. Case report
The case concerns a 47-year-old female patient with a previous
diagnosis of celiac disease and a long history of Hashimoto
thyroiditis requiring thyroid hormone replacement therapy. On
December 2010, the patient was admitted to the emergency
Table 1
Case series of advanced SBA treated with biologic agents.
Reference
Type
study
Cancer site
(N patients)
Mutational
status Treatment Line
Maximal
toxicity Outcomes
Clinical studies with chemotherapy and target agents in advanced SBA
Gulhati et al[7] Phase-2,
single arm
SBA, AAC (30) – CAPOX+BEV 1st Fatigue G3 (23%)
Hypertension G3 (23%)
Neutropenia G3 (20%)
Diarrhea G3 (10%)
ORR: 48.3%
PFS: 8.7 mo
OS: 12.9 mo
Aydin et al[8] Retrospective
(2 groups: A–B)
SBA (28) – CHEMO+BEV(A)
CHEMO(B)
1st Hematologic G3
(A: 25%, B: 6%)
ORR (A–B):
58.3–43.7% (p: 0.44)
PFS (A–B): 9.6–7.7
mo (p: 0.48)
OS (A–B): 18.5–14.8
mo (p: 0.73)
Takayoshi et al[9] Retrospective
(2 groups: A–B)
SBA, AAC (33) K-ras,
Her2-neu
CHEMO+BEV(A)
CHEMOalone-
CHEMO+CET(B)
1st, 2nd, 3rd – OS (A–B): 21.9–11.4
mo (p: 0.18)
Case series of advanced SBA treated with chemotherapy plus target agents
Santini et al[10] Case series Duodenum (2)
Jejunum (2)
WT K-ras (3) CET+ IRI based
CHEMO
1st (2)
2nd (2)
Neutropenia G3
Diarrhea G3
Rash G2
OS: 35, 19, 7
∗
, 17
∗
mo
De Dosso et al[11] Case report Ileum WT K-ras CET+ IRI 3rd Rash G2 OS: 27 mo
Tsang et al[12] Case report Jejunum – GEM+OXA+BEV 1st – OS: 12
∗
mo
Nagaraj et al[13] Case report Duodenum – FOLFOX+BEV 1st – OS: 96
∗
mo
AAC= ampullary adenocarcinoma, BEV=bevacizumab, CET= cetuximab, CHEMO= chemotherapy, GEM=gemcitabine, IRI= irinotecan, mo=months, ORR= overall response rate, OS=overall survival,
OXA= oxaliplatin, PFS=progression free survival, SBA= small bowel adenocarcinoma, WT=wilde type.
∗
Still alive at publication time.
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related to an intestinal obstruction. A computed tomography (CT)
scan revealed a severe jejunal stenosis without other pathologic
findings. An enteroscopy with jejunal biopsy showed poorly
differentiated cancerous cells suggestive for primary intestinal
cancer. A jejunal resection was subsequently carried out and the
diagnosis of mucinous adenocarcinoma of the jejunum confirmed:
pT4 pN1 (1/13) G3 V1 R0, Stadium IIIA sec AJCC 2010.
Immunohistochemistry for mismatch repair markers MLH-1 and
MSH-2was normal. A postoperativeCT scan, performed 1month
after surgery, revealed peritoneal carcinomatosis and abdominal
lymph nodes. Thus, first-line chemotherapy with 5-fluorouracil
plus oxaliplatin (FOLFOX) plus bevacizumab was delivered for a
yearwith stable disease as the best response.According to common
terminology criteria for adverse events toxicity criteria, G1
hypertension and G2 nausea were reported. Bevacizumab alone
was continued for further 5months, until August 2012,when aCT
scan showed a fast growing left pelvic mass (141318cm),
which showed increased glucose uptake at 18-f fdg positron
emission tomography/computed tomography (PET/CT). Patient
underwent a palliative resection of the mass. Histology confirmed
the small bowel origin of the tumor and showed wilde type (wt) of
both K-ras (codons 12 et 13) and BRAF genes. After a holiday
treatment period of 30months, duringwhich the patient retained a
good performance status along with stable radiologic features, on
March 2015, a CT scan revealed the appearance of a further
interaortocaval adenophathy. On account of the disease oligo-
progression, it was decided not to use conventional-dose
chemotherapy but enroll the patient in an experimental protocol
based on metronomic capecitabine and proton pump inhib-
itors.[14,15] During the study period she also received stereotactic
radiotherapy on the growing abdominal adenophathies. The
experimental treatmentwas continued for 8months until February22016, when a 18-f fdg PET/CT scan showed progressive disease in
lung, infradiaphragmatic, and supradiaphragmatic lymph nodes.
Based on both good performance status and response to first line
chemotherapy, a rechallenge with FOLFOX combined with
panitumumab was decided according to the Kras status. Three
months later a partial response was documented. Oxaliplatin was
discontinued after 6 cycles of treatment for the occurrence of
gastrointestinal toxicity up to G3. Moreover, because of G3
follicular skin rash, panitumumab was reduced to 80% of the full
dose. Since then, a maintenance capecitabine (625mg/mq bid die,
continuously) and panitumumab therapy is ongoing, with a
duration of 15months. Both skin rash andmucosistis ofG1 are the
only toxicities following this maintenance treatment while the last
18-f fdg PET/CThas confirmed a partial response.Overall survival
has by now reached 83 months from the diagnosis.3. Discussion
Few small prospective phase-2 studies have directly tested
chemotherapy in patients affected with advanced SBA.[2–5]
Oxaliplatin in combination with either 5-fluorouracil or capecita-
bine is commonly used in the frontline setting.[2,3] The combination
of mitomycin C, doxorubicin, and 5-fluorouracil has showed
minimal efficacy[4] and it is not usually employed. A combinationof
5-fluorouracil and irinotecan (FOLFIRI) regimen was evaluated
retrospectively as second line therapy after failure of first line
platinum-based chemotherapy, but results were modest.[16]
Recently, following the survival benefit reached with the use of
drug triplets in both CRC and pancreatic cancer, theNorth Central
Cancer Treatment Group performed the first pharmacogenetic-
based phase-2 study (N0543) in patients with advanced untreated
SBA, using a genotype-dosed combination of capecitabine,
irinotecan, and oxaliplatin.[5] Although the toxicity profile seemed
[2] Overman MJ, Varadhachary GR, Kopetz S, et al. Phase II study of
Table 2
Clinical trials with target therapy for advanced SBA.
Trial code Study design Setting Protocol Status
NCT01202409 II, not R WT K-ras SBA, AAC PAN Ongoing, not recruiting
NCT01208103 II, not R SBA, AAC CAP+OXA+BEV Ongoing, not recruiting
NCT03108131 II, not R RT COB+ATE Recruiting
NCT02034110 II, not R BRAF V600E mutated RT DAB+TRA Recruiting
NCT03095781 I, not R GIC PEM+XL888 Not yet open
NCT00987766 I, not R BPC, DC, AAC ERL+GEM+OXA Ongoing, not recruiting
NCT00005842 I, not R A/M C TIP+TRAS Completed
NCT00397384 I, not R GIC, HNC, NSCLC CET+ERL Completed
A/M C= advanced/metastatic cancer, AAC= ampullary adenocarcinoma, ATE=Atezolizumab, BEV=Bevacizumab, BPC=bilio-pancreatic cancer, CAP=Capecitabine, CET=Cetuximab, COB=Cobimetinib,
DAB=Dabrafenib, DC=duodenal cancer, ERL=Erlotinib, GEM=Gemcitabine, GIC=gastrintestinal cancer, HNC=head and neck cancer, NSCLC=non small cell lung cancer, OXA=Oxaliplatin, PAN=
Panitumumab, PEM=Pembrolizumab, R= randomized, RT= rare tumors, TIP=Tipifarnib, TRA=Trametinib, TRAS=Trastuzumab, XL888= inhibitor of HSP90.
Falcone et al. Medicine (2018) 97:3 www.md-journal.comto be favorable, conclusions about benefits of the addition of
irinotecan to oxaliplatin and fluorouracil could not be achieved.
The lack of clinical studies due to the rarity of SBA has implied for
the therapeutic decision-making the adoption of clinical guidelines
created for large bowel adenocarcinoma. Although combination
treatments with bevacizumab have generated encouraging results,
no conclusion can be drawnat present. Indeed, the interpretation of
data should consider the following remarks: small sample of
patients included, heterogeneity of the study population (SBA with
or without ampullary adenocarcinoma), nature of the study,
different chemotherapy protocols (FOLFOX-FOLFIRI-CAPOX-
SOX) used with bevacizumab and finally, variability of patients
set.[7–9] Evena lower level of evidence supports theoptionof ananti-
EGFR therapy. In fact, only few patients affectedwith SBA received
cetuximab while none was treated with panitumumab until
now.[10,11] These monoclonal antibodies, alone or combined with
chemotherapy, arewidelyadopted for the treatmentofpatientswith
wild-type RAt Sarcoma (RAS) metastatic CRC. However, very
limited data pertain the use of maintenance anti-EGFR therapy.[17]
The present case referred to a patient affected with wt RAS,
metastatic SBA who obtained both partial response and a long
progression free survival (PFS) following an induction therapywith
FOLFOX and panitumumab. A maintenance regimen with
fluoropyrimidine and anti-EGFR antibody was started and carried
out with a good tolerability. To the best of our knowledge no other
similar experience has been presented up to now.
4. Conclusion
The use of chemotherapy in SBA is solely supported by level II
evidence. For such reason, anticancer regimens suitable for CRC
are usually applied. Furthermore, just anecdotal experiences
about the use of anti-EGFR monoclonal antibodies have been
reported. Although some clinical trials are ongoing to test target
therapies in advanced or metastatic SBA (Table 2), there is the
need of further comparative studies aimed at better define therapy
of this orphan disease.
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